



Emerging Perspectives on Breast Cancer and Antibody–Drug Conjugates Treatment: From Bench to Bedside

Guest Editor:

Dr. Alberto Zambelli

1. Medical Oncology and
Hematology Unit, IRCCS
Humanitas Research Hospital,
20089 Rozzano, Italy
2. Department of Biomedical
Sciences, Humanitas University,
20072 Pieve Emanuele, Italy

Deadline for manuscript
submissions:

31 August 2024

Message from the Guest Editor

In recent years, the therapeutic landscape of breast cancer has transitioned from broad-spectrum chemotherapies to precision-targeted treatments, rendering the path to optimizing patient outcomes increasingly complex. Antibody–drug conjugates (ADCs) stand out as a pioneering treatment strategy, promising a transformation in breast cancer care.

ADCs embody the epitome of oncological innovation. Their innovative design, characterized by targeted drug delivery, offers a novel paradigm in cancer therapeutics.

This Special Issue, entitled "Emerging Perspectives on Breast Cancer and Antibody–Drug Conjugates Treatment: from Bench to Bedside", aims to explore the depths of knowledge surrounding ADCs in the preclinical and clinical arena. We welcome the submission of insightful research articles and reviews that delve into mechanisms of action, biomarker identification, and toxicity management, and those that aim to unravel resistance patterns and strategize treatment pathways. Our aim is to present a comprehensive overview of the field while promoting a more profound and holistic understanding of the topic.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)